ArticleOncoTargets and therapy2016

Risk of brain metastasis reduced after erlotinib treatment in advanced pulmonary adenocarcinoma patients with sensitive EGFR mutation.

Jing Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.